OAKDALE, Minn.--(BUSINESS WIRE)--BlueAllele® Corporation, a biotechnology company focused on advancing transformational gene editing technologies, filed a patent infringement lawsuit against Intellia Therapeutics in the United States District Court for the District of Delaware. The complaint alleges infringement of BlueAllele’s bi-directional insertion template patents, which cover the company’s transformational platform used in the development and treatment of genetic diseases.
The novel design of BlueAllele’s bi-directional insertion template technology has unlocked the full potential of the cell’s highly active NHEJ pathway. Use of the patented bi-directional insertion template technology can increase the efficacy of gene editing events, improve safety, and allow development of therapeutics for a wide range of diseases. As alleged in the complaint, Intellia has utilized BlueAllele’s patented platform technology to advance internal programs as well as external collaboration programs.
BlueAllele develops methodologies for single-dose in vivo treatments to cure the most debilitating and devastating genetic diseases. BlueAllele has actively protected its inventions resulting in a substantial patent estate. “BlueAllele’s patents cover our novel and innovative technology for achieving precise gene editing,” said Dr. Nicholas J. Baltes, BlueAllele’s chief scientific officer. “Protecting BlueAllele’s intellectual property is a critical part of our business.”
BlueAllele has expanded upon its bi-directional insertion template technology with the design of additional platforms for treating specific classes of genetic diseases, including bi-directional templates with RNAi cassettes for autosomal dominant diseases and functions to remove unwanted gene products while simultaneously restoring normal protein function. Further, BlueAllele has developed bi-directional templates with dual terminators designed to address repeat expansion diseases and functions to prevent transcription through the expansion.
“BlueAllele has been at the forefront of gene editing technologies,” said Joseph B. Saluri, BlueAllele’s chief executive officer. “The purpose of this lawsuit is to protect our patent rights and to ensure our ability to continue conceiving and advancing transformational technologies for patients with genetic diseases.”
BlueAllele Corporation is being represented in the lawsuit by Fish & Richardson P.C. and Schwartz Law Firm.
About BlueAllele
BlueAllele Corporation is a biotechnology company committed to advancing transformational gene editing technologies, including its patented PALIDON®, PALIDON+™, and PALIDON DT™ repair template platforms. For more information, visit www.blueallele.com.
About BlueAllele’s Patents
The patents asserted in the complaint are U.S. patent 11,091,756, U.S. Patent 11,254,930 and U.S. patent 11,365,407.
The ’756, ’930, and ’407 Patents are exclusively owned by BlueAllele Corporation and cover the company’s bi-directional insertion template technology for gene editing.
BlueAllele maintains patents in various jurisdictions around the world on its bi-directional insertion template technology.
BlueAllele®, PALIDON®, PALIDON+™, and PALIDON DT™ are registered trademarks of BlueAllele Corporation.
